CBD for Psoriasis – Must Read New Research

¹Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010;49(12):1351-1361. doi:10.1111/j.1365-4632.2010.04570.x

²Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006;155(4):729-736. doi:10.1111/j.1365-2133.2006.07405.x

³Boehncke, W.H., Schön M.P. (2015). Psoriasis. The Lancet, 386(9997), 983-994. 

⁴Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401-407. doi:10.1016/s0190-9622(99)70112-x

⁵Mayo Clinic (2019, Oct. 9). Prednisone and other corticosteroids

⁶Oakley AM, Wyllie K. A review of ultraviolet treatment for psoriasis at Waikato Hospital. Australas J Dermatol. 1996;37(3):132-136. doi:10.1111/j.1440-0960.1996.tb01030.x

7Briffa DV, Warin AP. Photochemotherapy in psoriasis: a review. J R Soc Med. 1979;72(6):440-446. 

⁸Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833. Published 2018 Mar 13. doi:10.3390/ijms19030833

⁹Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5(5):400-411. doi:10.1038/nri1602

¹⁰Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2007;45(2):87-92. doi:10.1016/j.jdermsci.2006.10.009

11Ständer S, Reinhardt HW, Luger TA. Topische Cannabinoidagonisten. Eine effektive, neue Möglichkeit zur Behandlung von chronischem Pruritus [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. Hautarzt. 2006;57(9):801-807.